1 day ago
Gland Pharma Shares Slip Amid Block Deal Report
Gland Pharma shares fell by more than 2% after a report about a large share trade.
The proposed minimum price for that trade was Rs 2,990 per share.
Even after the fall, the shares have risen 72.99% during 2026.
They are up by Rs 1,251.90 so far this year.
Brokerage 360 One Capital remains positive about the company.
It expects Gland Pharma’s CDMO business to grow.
The brokerage also expects profit margins to improve from about 28% to 34-35%.
It set a price target of Rs 3,050 per share.
Gland Pharma shares fell more than 2% amid a reported block deal.
The proposed block deal floor price was Rs 2,990 per share.
Gland Pharma shares have gained 72.99% in 2026, or Rs 1,251.90 year to date.
360 One Capital retained its positive view and set a target price of Rs 3,050.
The brokerage expects CDMO growth, revenue and profit expansion, and improved EBITDA margins.
- Who
- Gland Pharma and 360 One Capital.
- What
- Gland Pharma shares fell over 2% amid a reported block deal, while 360 One Capital maintained a positive outlook.
- Where
- When
- During 2026; the exact date of the reported block deal is not stated.
- Why
- The share decline was reported amid block deal activity; 360 One Capital cited expected CDMO expansion as a reason for its positive outlook.
Market Reaction
Brokerage Outlook
Near-term share performance
Market Reaction
Gland Pharma shares fell more than 2% amid reported block deal activity.
Brokerage Outlook
360 One Capital maintained a positive view and set a target price of Rs 3,050 per share.
Growth expectations
Market Reaction
The block deal report created selling pressure, although the article does not identify the buyer or seller.
Brokerage Outlook
360 One Capital expects the CDMO business to scale up, supporting about 20% constant-currency growth and higher EBITDA margins.
Key facts
- Share movement
- Gland Pharma shares fell over 2%.
- Proposed floor price
- Rs 2,990 per share.
- 2026 gain
- 72.99%, according to the report.
- Year-to-date increase
- Rs 1,251.90.
- Brokerage
- 360 One Capital retained its positive view.
- Target price
- Rs 3,050 per share.
- Expected EBITDA margin
- Around 34-35%, compared with about 28% currently.
- Projected growth
- 360 One Capital expects 13% revenue CAGR and 21% PAT CAGR over FY26-FY28 estimates.
Quotes
360 One Capital
Brokerage that retained a positive view on Gland Pharma
“We expect Gland to clock 13%/21% Revenue/PAT CAGR over FY2628e. At the CMP of Rs 2922, Gland trades at 39x/31x FY27/FY28 EPS of Rs 75.1/Rs 93.1.”
businesstoday.in
Sources
Related news
Jefferies names four healthcare stocks with earnings upside
Gland Pharma Invests ₹175 Crore in US Subsidiary Expansion
Promoter Stake Sales Draw Institutional Interest in Three Indian Stocks
InCred Equities Sees 39% Upside for GMM Pfaudler
Sterlite Technologies Surges 700% as FY29 Growth Plan Fuels Rally
Indegene Shares Rise as Motilal Oswal Upgrades Stock, Sets Target
India’s Falling Stocks Hide Pharma and AI Infrastructure Winners
Fosun Pharma Stake Sale Takes Holding Below 50%
